William Reynolds, MD
Internal Medicine · Enterprise, ALNPI 1134178668
Payments from drug & device makers
Across 172 payments — averaging $13.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$483
- Johnson & Johnson$332
- Astellas Pharma US Inc$277
- AstraZeneca$237
- GSK$202
- Pfizer$127
- plus $692 from 18 others
What the payments were for
- Food & beverage$2,345100%
- Education$50%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 36 | $483 |
| Johnson & Johnson | 45 | $332 |
| Astellas Pharma US Inc | 13 | $277 |
| AstraZeneca | 12 | $237 |
| GSK | 11 | $202 |
| Pfizer | 12 | $127 |
| AbbVie(2 entities) | 7 | $125 |
| Novartis | 6 | $95 |
| Amgen | 5 | $71 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $61 |
| Teva Pharmaceuticals USA, Inc. | 4 | $50 |
| Sunovion Pharmaceuticals Inc. | 3 | $47 |
| Baxter Healthcare | 1 | $47 |
| Dexcom, Inc. | 2 | $29 |
| Sanofi-aventis U.S. LLC | 2 | $25 |
| Lilly USA, LLC | 2 | $22 |
| Biohaven Pharmaceuticals, Inc. | 1 | $20 |
| Supernus Pharmaceuticals, Inc. | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| Philips North America LLC | 1 | $15 |
| Amarin Pharma, Inc. | 1 | $15 |
| Bayer | 1 | $13 |
| Otsuka America Pharmaceutical, Inc. | 1 | $13 |
| Boehringer Ingelheim | 1 | $12 |
How this compares
$2,350 in reported general payments places this provider in the 70th percentile of 1,533 internal medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 156 | $170,438 |
| MounjaroTirzepatide | 110 | $144,413 |
| OzempicSemaglutide | 123 | $129,923 |
| EliquisApixaban | 149 | $121,909 |
| XareltoRivaroxaban | 107 | $89,341 |
| JanuviaSitagliptin Phosphate | 73 | $73,143 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 65 | $67,904 |
| TrulicityDulaglutide | 26 | $39,426 |
| FarxigaDapagliflozin Propanediol | 37 | $29,738 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 51 | $23,495 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 27 | $20,973 |
| Breo ElliptaFluticasone/Vilanterol | 42 | $20,660 |
| MyrbetriqMirabegron | 21 | $20,011 |
| RybelsusSemaglutide | 12 | $19,090 |
| LinzessLinaclotide | 22 | $13,664 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Combivent Respimat | $12 | $191,411183 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humulin 70-30 | $22 | $188,949151 claims |
| Novo NordiskOzempic, Rybelsus | $483 | $149,014135 claims |
| PfizerEliquis | $127 | $121,909149 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $202 | $112,059158 claims |
| Johnson & JohnsonXarelto, Invokana | $332 | $99,986119 claims |
| AstraZenecaFarxiga, Symbicort | $237 | $33,92155 claims |
| Astellas Pharma US IncMyrbetriq | $277 | $20,01121 claims |
| AbbVieLinzess | $125 | $13,66422 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,533 internal medicine providers in Alabama.
Other internal medicine in Enterprise
- Harry StuddardMobile$12.9M
- Almena FreeAnniston$12.7M
- Hayes WilliamsVestavia$10.4M
- David DeatkineBirmingham$8M
- James SullivanBirmingham$6M
- Ramy TomaBirmingham$5.1M
- Barry McLeanHomewood$4M
- William KirbyBirmingham$2.3M
- Saadat AnsariHuntsville$2.1M
- Gregory FlippoTrussville$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.